Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 9/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | ACHE | P22303 | 2/20 | 0.59 |
| ▸ | BACE1 | P56817 | 2/20 | 0.59 |
| ▸ | AURKA | O14965 | 1/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.55 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.55 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22291036 | 0.90 | ENPP1 (0.72) | ENPP1MAPK1ACHEBACE1AURKA | |
| SCHEMBL20814063 | 0.88 | ENPP1 (0.68) | ENPP1MAPK1ACHEBACE1AURKA | |
| Hydrochloric Acid SCHEMBL10797414 | 0.85 | ENPP1 (0.61) | ENPP1MAPK1ACHEBACE1AURKA | |
| SCHEMBL11484522 | 0.84 | ENPP1 (0.62) | ENPP1MAPK1ACHEBACE1PDGFRB | |
| SCHEMBL20782445 | 0.84 | ENPP1 (0.74) | ENPP1MAPK1ACHEBACE1AURKA | |
| SCHEMBL22300263 | 0.84 | ENPP1 (0.64) | ENPP1MAPK1ACHEBACE1AURKA | |
| SCHEMBL20305205 | 0.83 | ENPP1 (0.92) | ENPP1MAPK1ACHEBACE1PDE10A | |
| SCHEMBL22407331 | 0.83 | ENPP1 (0.66) | ENPP1MAPK1ACHEBACE1PDGFRB | |
| SCHEMBL22300102 | 0.82 | ENPP1 (0.78) | ENPP1MAPK1ACHEBACE1AURKA | |
| SCHEMBL22407367 | 0.82 | ENPP1 (0.70) | ENPP1MAPK1ACHEBACE1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059218-A1 | ENPP1 Inhibitors and Methods of Modulating Immune Response | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2025-02-20 | — | — | US | disclosed |
| CN-113677350-B | ENPP1 inhibitors and methods of modulating immune responses | 里兰斯坦福初级大学理事会 | 2025-01-14 | — | — | CN | disclosed |
| US-20220289775-A1 | ENPP1 Inhibitors and Methods of Modulating Immune Response | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-09-15 | — | — | US | disclosed |
| EP-3917536-A1 | ENPP1 INHIBITORS AND METHODS OF MODULATING IMMUNE RESPONSE | The Board of Trustees of the Leland Stanford Junior University (US) | 2021-12-08 | — | — | EP | disclosed |
| CN-113677350-A | ENPP1 inhibitors and methods of modulating immune responses | 里兰斯坦福初级大学理事会 | 2021-11-19 | — | — | CN | disclosed |
| WO-2020160333-A1 | ENPP1 INHIBITORS AND METHODS OF MODULATING IMMUNE RESPONSE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289775-A1 | ENPP1 Inhibitors and Methods of Modulating Immune Response | ENPP1, STING1, ENPP2 | ENPP1 1/4885MAPK1 778/4885ACHE 2269/4885 |
| US-20250059218-A1 | ENPP1 Inhibitors and Methods of Modulating Immune Response | ENPP1, STING1, ENPP2 | ENPP1 1/4885MAPK1 778/4885ACHE 2269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.